Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 20/20 | 0.89 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.89 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.77 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10322136 | 0.94 | ADORA3 (1.00) | ADORA3ADORA2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL16361697 | 0.94 | ADORA3 (1.00) | ADORA3ADORA2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL10323827 | 0.93 | ADORA3 (1.00) | ADORA3ADORA2A | |
| SCHEMBL16361550 | 0.93 | ADORA3 (1.00) | ADORA3ADORA2A | |
| SCHEMBL10321790 | 0.91 | ADORA3 (1.00) | ADORA3ADORA2A | |
| SCHEMBL16361709 | 0.91 | ADORA3 (1.00) | ADORA3ADORA2A | |
| SCHEMBL10322205 | 0.91 | ADORA3 (1.00) | ADORA3ADORA2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL10320614 | 0.91 | ADORA3 (1.00) | ADORA3ADORA2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL10321999 | 0.91 | ADORA3 (1.00) | ADORA3ADORA2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL16361549 | 0.91 | ADORA3 (1.00) | ADORA3ADORA2ASLC6A2SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916570-B2 | A3 adenosine receptor agonists and antagonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-12-23 | — | — | US | disclosed |